PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma von Nghiem, Paul T, Bhatia, Shailender, Lipson, Evan J, Kudchadkar, Ragini R, Miller, Natalie J, Annamalai, Lakshmanan, Berry, Sneha, Chartash, Elliot K, Daud, Adil, Fling, Steven P, Friedlander, Philip A, Kluger, Harriet M, Kohrt, Holbrook E, Lundgren, Lisa, Margolin, Kim, Mitchell, Alan, Olencki, Thomas, Pardoll, Drew M, Reddy, Sunil A, Shantha, Erica M, Sharfman, William H, Sharon, Elad, Shemanski, Lynn R, Shinohara, Michi M, Sunshine, Joel C, Taube, Janis M, Thompson, John A, Townson, Steven M, Yearley, Jennifer H, Topalian, Suzanne L, Cheever, Martin A

Volltext

Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study von Cohen, Graham, Rapoport, Bernardo, Chan, Sze W, Ruff, Paul, Arance, Ana, Mujika Eizmendi, Karmele, Houghton, Baerin, Brown, Michael P, Zielinski, Robert M, Muñoz Couselo, Eva, Lyle, Megan, Anderson, James R, Jain, Lokesh, de Alwis, Dinesh, Lala, Mallika, Akala, Omobolaji, Chartash, Elliot, Jacobs, Conrad

Volltext

Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy von Guelen, Lars, Fischmann, Thierry O, Wong, Jerelyn, Mauze, Smita, Guadagnoli, Marco, Bąbała, Nikolina, Wagenaars, Jozef, Juan, Veronica, Rosen, David, Prosise, Winnie, Habraken, Maurice, Lodewijks, Imke, Gu, Danling, Stammen-Vogelzangs, Judith, Yu, Ying, Baker, Jeanne, Lutje Hulsik, David, Driessen-Engels, Lilian, Malashock, Dan, Kreijtz, Joost, Bertens, Astrid, de Vries, Evert, Bovens, Astrid, Bramer, Arne, Zhang, Yiwei, Wnek, Richard, Troth, Sean, Chartash, Elliot, Dobrenkov, Konstantin, Sadekova, Svetlana, van Elsas, Andrea, Cheung, Jason K, Fayadat-Dilman, Laurence, Borst, Jannie, Beebe, Amy M, Van Eenennaam, Hans

Volltext

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving co... von Weisman, Michael H., Moreland, Larry W., Furst, Daniel E., Weinblatt, Michael E., Keystone, Edward C., Paulus, Harold E., Teoh, Leah S., Velagapudi, Raja B., Noertersheuser, Peter A., Granneman, G.Richard, Fischkoff, Steven A., Chartash, Elliot K.

Volltext

First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients... von Geva, Ravit, Voskoboynik, Mark, Dobrenkov, Konstantin, Mayawala, Kapil, Gwo, Jennifer, Wnek, Richard, Chartash, Elliot, Long, Georgina V.

Volltext

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation von Lala, Mallika, Li, Tommy Ruosi, de Alwis, Dinesh P., Sinha, Vikram, Mayawala, Kapil, Yamamoto, Noboru, Siu, Lillian L., Chartash, Elliot, Aboshady, Hesham, Jain, Lokesh

Volltext

Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors von Papadopoulos, Kyriakos P, Autio, Karen, Golan, Talia, Dobrenkov, Konstantin, Chartash, Elliot, Chen, Qiusheng, Wnek, Richard, Long, Georgina V

Volltext

Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis von Kimball, Alexa B, Gordon, Kenneth B, Langley, Richard G, Menter, Alan, Chartash, Elliot K, Valdes, Joaquin

Volltext

Phase I Study of MK-4166, an Anti-Human Glucocorticoid-Induced Tumor Necrosis Factor Receptor Antibody, Alone or With Pembrolizumab in Advanced Solid Tumors von Papadopoulos, Kyriakos P., Autio, Karen, Golan, Talia, Dobrenkov, Konstantin, Chartash, Elliot, Chen, Qiusheng, Wnek, Richard, Long, Georgina V.

Volltext

Abstract CT042: Pembrolizumab 400 mg Q6W dosing: First clinical outcomes data from Keynote-555 cohort B in metastatic melanoma patients von Lala, Mallika, Akala, Omobolaji, Chartash, Elliot, Kalabis, Mizuho, Su, Shu-Chih, de Alwis, Dinesh, Sinha, Vikram, Jain, Lokesh

Volltext

Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma von Cohen, Graham, Rapoport, Bernardo, Chan, Sze W, Ruff, Paul, Arance, Ana, Mujika Eizmendi, Karmele, Houghton, Baerin, Brown, Michael P, Zielinski, Robert M, Muñoz Couselo, Eva, Lyle, Megan, Anderson, James R, Jain, Lokesh, de Alwis, Dinesh, Lala, Mallika, Akala, Omobolaji, Chartash, Elliot, Jacobs, Conrad

Volltext

First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembr... von Geva, Ravit, Voskoboynik, Mark, Beebe, Amy M, Gwo, Jennifer, Dobrenkov, Konstantin, Chartash, Elliot, Long, Georgina V.

Volltext

A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation von Lala, Mallika, Li, Mengyao, Sinha, Vikram, de Alwis, Dinesh, Chartash, Elliot, Jain, Lokesh

Volltext

Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with... von Papadopoulos, Kyriakos P., Autio, Karen A., Golan, Talia, Dobrenkov, Konstantin, Chartash, Elliot, Li, Xiaoyun Nicole, Wnek, Richard, Long, Georgina V.

Volltext

Abstract CT143: Pembrolizumab bioavailability after subcutaneous administration: analysis from the KEYNOTE-555 Cohort A in metastatic melanoma von Jacobs, Conrad R., Rapoport, Bernardo Leon, Cohen, Graham Lawrence, Lala, Mallika, Silva, Carolina De Miranda, Vaddady, Pavan, Gheyas, Ferdous, de Alwis, Dinesh, Sinha, Vikram, Akala, Omobolaji Oyekunle, Chartash, Elliot, Jain, Lokesh

Volltext

KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab (pembro) 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma von Jacobs, Conrad R., Rapoport, Bernardo Leon, Chan, Sze Wai, Ruff, Paul, Arance, Ana Maria, Mujika, Karmele, Anderson, James Robert, Lala, Mallika, Jain, Lokesh, Akala, Omobolaji Oyekunle, Chartash, Elliot, Cohen, Graham Lawrence

Volltext

Corrigendum to “A six-weekly (Q6W) dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation” [Eur J Canc 131 (2020) 68–75] von Lala, Mallika, Li, Tommy Ruosi, de Alwis, Dinesh P., Sinha, Vikram, Mayawala, Kapil, Li, Mengyao, Yamamoto, Noboru, Siu, Lillian L., Chartash, Elliot, Aboshady, Hesham, Jain, Lokesh

Volltext

Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis: Results of a Randomized, Place... von Kimball, Alexa B, Gordon, Kenneth B, Langley, Richard G, Menter, Alan, Chartash, Elliot K, Valdes, Joaquin

Volltext

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis r... von Keystone, Edward C., Kavanaugh, Arthur F., Sharp, John T., Tannenbaum, Hyman, Hua, Ye, Teoh, Leah S., Fischkoff, Steven A., Chartash, Elliot K.

Volltext

P-146 Assessment of Immune Responses to Pneumococcal and Influenza Vaccines in Patients Receiving Certolizumab Pegol: ERRATUM von Kivitz, Alan, Schechtman, Joy, Texter, Michele, Fichtner, Andreas, Chartash, Elliot

Volltext